Phio Pharmaceuticals Corp. (PHIO)
0.808
+0.01
(+1.00%)
USD |
NASDAQ |
Nov 06, 10:25
Phio Pharmaceuticals Net Income (Quarterly) : -4.138M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -4.138M |
| March 31, 2026 | -4.003M |
| December 31, 2025 | -2.371M |
| September 30, 2025 | -2.392M |
| June 30, 2025 | -2.166M |
| March 31, 2025 | -1.769M |
| December 31, 2024 | -1.626M |
| September 30, 2024 | -1.524M |
| June 30, 2024 | -1.846M |
| March 31, 2024 | -2.154M |
| December 31, 2023 | -1.895M |
| September 30, 2023 | -2.78M |
| June 30, 2023 | -2.549M |
| March 31, 2023 | -3.602M |
| December 31, 2022 | -2.731M |
| September 30, 2022 | -3.576M |
| June 30, 2022 | -2.531M |
| March 31, 2022 | -2.642M |
| December 31, 2021 | -3.451M |
| September 30, 2021 | -3.742M |
| June 30, 2021 | -2.687M |
| March 31, 2021 | -3.407M |
| December 31, 2020 | -2.462M |
| September 30, 2020 | -2.309M |
| June 30, 2020 | -1.672M |
| Date | Value |
|---|---|
| March 31, 2020 | -2.351M |
| December 31, 2019 | -2.66M |
| September 30, 2019 | -2.094M |
| June 30, 2019 | -2.035M |
| March 31, 2019 | -2.119M |
| December 31, 2018 | -1.727M |
| September 30, 2018 | -1.493M |
| June 30, 2018 | -1.901M |
| March 31, 2018 | -2.239M |
| December 31, 2017 | -2.002M |
| September 30, 2017 | -2.476M |
| June 30, 2017 | -2.514M |
| March 31, 2017 | -5.46M |
| December 31, 2016 | -2.339M |
| September 30, 2016 | -2.212M |
| June 30, 2016 | -2.212M |
| March 31, 2016 | -2.231M |
| December 31, 2015 | -2.616M |
| September 30, 2015 | -2.496M |
| June 30, 2015 | -2.166M |
| March 31, 2015 | -2.945M |
| December 31, 2014 | -2.304M |
| September 30, 2014 | -2.206M |
| June 30, 2014 | -2.006M |
| March 31, 2014 | -2.284M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| CapForce, Inc. | 42.47M |
| Agenus, Inc. | -0.567M |
| Amgen, Inc. | 3.864B |
| Anika Therapeutics, Inc. | 3.309M |
| BioCryst Pharmaceuticals, Inc. | 37.92M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 4.138M |
| EPS Diluted (Quarterly) | -0.3562 |
| Enterprise Value | -3.702M |
| Earnings Yield | -166.1% |
| Normalized Earnings Yield | -166.13 |